Our Transactions
Leadership across the largest and most complex situations
Lead Financial Advisor
on its pending €8.0 billion
acquisition of
from Vodafone Group
2024
Exclusive Financial Advisor
on its pending ~$2.3 billion
acquisition of
2024
Independent Financial Advisor
on its pending acquisition of three fill-finish sites for an upfront payment of $11 billion from Novo Holdings following its $16.5 billion acquisition of Catalent
2024
Exclusive Financial Advisor
on its pending ~$35 billion
acquisition of
2024
Exclusive Financial Advisor
on its pending ~$12.6 billion
sale to
2024
Lead Financial Advisor
on its pending $11.5 billion
all-stock merger with
2024
Lead Financial Advisor
on its pending ~$13.4 billion
sale to
2023
Financial Advisor
on its pending ~$14.9 billion
sale to
2023
Financial Advisor
on its pending $60 billion
all-stock acquisition of
2023
Financial Advisor
on its up to $5.8 billion
acquisition of
2023
Financial Advisor
on its pending ~$20 billion
merger with
2023
Lead Left Bookrunner
$300 million
Follow-on Offering
2023
Exclusive Financial Advisor
on its chapter 11 restructuring of ~$1.9 billion of debt and $125 million DIP ABL financing
2023
Active Bookrunner
$1.1 billion IPO & $1.6 billion
Follow-on Offering
2023
Exclusive Financial Advisor
on its pre-packaged chapter 11 restructuring of ~$3.6 billion of debt and preferred equity
2023
Lead Financial Advisor
on its ~$36 billion
spin-off of
2021
Anouncement Date1
Status
Transaction
Value (M)
February 16, 2024
Closed
Acted as an Active Bookrunner on GE HealthCare’s Secondary Offering
$1,230
February 15, 2024
Pending
Acting as Exclusive Placement Agent for Sage Geosystem's Series A Capital Raise
$17
February 13, 2024
Pending
Advising Buckthorn Partners on its sale of Coretrax to Expro Group Holdings
~$210
February 12, 2024
Closed
Acted as Global Capital Adviser to Raith Capital Partners on the fundraise for Raith Real Estate Fund III
$539
February 8, 2024
Closed
Acted as a Placement Agent on Mineralys Therapeutics’ Private Placement
$120
February 8, 2024
Closed
Advised Autolus Therapeutics on its Strategic Collaboration with BioNTech to develop, manufacture and commercialize autologous cell therapies
$250
February 6, 2024
Closed
Advised Kazyon on its acquisition of a 50% stake in Al Dukan
SAR 250
February 6, 2024
Closed
Acted as an Active Bookrunner on Jasper Therapeutics' Underwritten Equity Offering
$50
February 6, 2024
Pending
Advising Haveli on its acquisition of ZeroFox
~$350
February 5, 2024
Pending
Advising Novo Nordisk on its acquisition of three fill-finish sites from Novo Holdings following its acquisition of Catalent
$11,000
1Announcement date for M&A transactions represents the date publicly announced; announcement date for restructurings represents the date publicly announced or filed; announcement date for capital markets transactions represents the pricing date.